TRIM5alpha
- PMID: 20012523
- DOI: 10.1007/978-3-642-02175-6_3
TRIM5alpha
Abstract
TRIM5alpha protein blocks retroviral replication at early postentry stage reducing the accumulation of reverse transcriptase products. TRIM5alpha proteins of Old World primates restrict HIV-1 infection whereas TRIM5alpha proteins of most New World monkeys restrict SIV(mac) infection. TRIM5alpha protein has a RING domain, B-box 2 domain, coiled-coil domain, and PRYSPRY domain. The PRYSPRY domain of TRIM5alpha determines viral specificity and restriction potency by mediating recognition of the retroviral capsid. The coiled-coil domain is essential for TRIM5alpha oligomerization, which contributes to binding avidity for the viral capsid. The RING domain and B-box 2 domain are required for efficient restriction activity of TRIM5alpha protein but the mechanisms remain to be defined.
Similar articles
-
The control of viral infection by tripartite motif proteins and cyclophilin A.Retrovirology. 2007 Jun 12;4:40. doi: 10.1186/1742-4690-4-40. Retrovirology. 2007. PMID: 17565686 Free PMC article. Review.
-
Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction.J Virol. 2005 Mar;79(5):3139-45. doi: 10.1128/JVI.79.5.3139-3145.2005. J Virol. 2005. PMID: 15709033 Free PMC article.
-
Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp.Virology. 2007 Dec 20;369(2):400-10. doi: 10.1016/j.virol.2007.08.032. Epub 2007 Oct 24. Virology. 2007. PMID: 17920096 Free PMC article.
-
The TRIM5alpha B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higher-order self-association.J Virol. 2008 Dec;82(23):11495-502. doi: 10.1128/JVI.01548-08. Epub 2008 Sep 17. J Virol. 2008. PMID: 18799578 Free PMC article.
-
Retroviral restriction factors TRIM5α: therapeutic strategy to inhibit HIV-1 replication.Curr Med Chem. 2011;18(17):2649-54. doi: 10.2174/092986711795933687. Curr Med Chem. 2011. PMID: 21568899 Review.
Cited by
-
The Evolutionary Histories of Antiretroviral Proteins SERINC3 and SERINC5 Do Not Support an Evolutionary Arms Race in Primates.J Virol. 2016 Aug 26;90(18):8085-9. doi: 10.1128/JVI.00972-16. Print 2016 Sep 15. J Virol. 2016. PMID: 27356902 Free PMC article.
-
Antiviral TRIMs: friend or foe in autoimmune and autoinflammatory disease?Nat Rev Immunol. 2011 Aug 25;11(9):617-25. doi: 10.1038/nri3043. Nat Rev Immunol. 2011. PMID: 21866173
-
HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.Retrovirology. 2011 Dec 15;8:103. doi: 10.1186/1742-4690-8-103. Retrovirology. 2011. PMID: 22171785 Free PMC article.
-
TRIM5 inhibits the replication of Senecavirus A by promoting the RIG-I-mediated type I interferon antiviral response.Vet Res. 2024 Aug 14;55(1):101. doi: 10.1186/s13567-024-01354-2. Vet Res. 2024. PMID: 39143491 Free PMC article.
-
Misdirection of membrane trafficking by HIV-1 Vpu and Nef: Keys to viral virulence and persistence.Cell Logist. 2011 May;1(3):90-102. doi: 10.4161/cl.1.3.16708. Cell Logist. 2011. PMID: 21922073 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
